Characterizing patients and outcomes in severe tricuspid regurgitation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize patients eligible for transcatheter tricuspid valve interventions (TTVI) by enrolling individuals referred to tertiary-care centers for severe tricuspid regurgitation. The study will describe patient profiles, identify common reasons for disqualification from TTVI, and evaluate both the immediate and long-term efficacy and safety of the intervention. Participants will undergo standard qualification procedures followed by clinical examinations, echocardiography, and laboratory tests to monitor outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* tricuspid regurgitation
* qualification for transcatheter tricuspid valve intervention

Exclusion Criteria:

* tricuspid regurgitation qualified for surgical treatment
* concomitant left heart valve disease qualified for surgical treatment
* multivessel coronary artery disease qualified for coronary artery bypass grafting
* lack of patient's consent to enter the registry

Where it's running

• First Department of Cardiology, Medical University of Warsaw
  Warsaw, Masovian Voivodeship, Poland Recruiting

Study contacts

• Principal investigator: Adam Rdzanek, MD PhD — First Department of Cardiology, Medical University of Warsaw
• Study coordinator: Adam Rdzanek, MD PhD
• Email: adam.rdzanek@wum.edu.pl
• Phone: 4822 599 19 51

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Apple Watch data to predict heart failure outcomes

  This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.

  Recruiting University Medical Center Goettingen · Goettigen, Lower Saxony · NCT06819618

• Registry for transcatheter repair of tricuspid regurgitation

  This study is collecting information on how well transcatheter repairs or replacements for the tricuspid valve work for people with tricuspid regurgitation to help improve treatment choices for them.

  Recruiting LMU Klinikum · Munich, Bavaria · NCT06307262

• Comparing Aortix Device to Diuretics for Acute Heart Failure

  This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.

  Recruiting at 33 sites Procyrion · Phoenix, Arizona and 49 other locations · NCT05677100

• Using AI to improve heart disease management in rural Australia

  This study is testing whether using artificial intelligence to help with heart scans can improve care for people with heart problems living in rural Australia.

  Recruiting Baker Heart and Diabetes Institute · Alice Springs, Northern Territory · NCT05558605

• Follow-up of patients treated with TricValve® for heart valve issues

  This study follows patients who have had treatment for severe tricuspid regurgitation using the TricValve® system to see how well the valve is working over the next five years.

  Recruiting at 12 sites P+F Products + Features GmbH · Sankt Pölten, Lower Austria and 27 other locations · NCT05114850

• Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS

  Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing · NCT07912086

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.